EAY191 / ComboMATCH
A precision medicine cancer trial in development
Updated January 24, 2023
The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), National Cancer Institute (NCI) and other cooperative research groups are developing ComboMATCH, a successor to the NCI-MATCH precision medicine trial. Like the original trial, ComboMATCH will be a signal-seeking study. While NCI-MATCH treatments mostly consist of single drugs, ComboMATCH will test combinations of anti-cancer drugs. The principal is to overcome drug resistance to single-agent therapy by developing genomically-directed targeted agent combinations.
All combinations in the new trial will be supported by robust, preclinical in vivo evidence. The hypothesis behind this trial is that in vivo evidence, in particular, patient-derived xenograft (PDX) and cell-line-derived xenograft (CDX) data, can be used to predict the benefit of drug combination therapy in multiple specified patient subgroups.
ComboMATCH will have an overall Patient Registration Trial and several treatment trials. The Patient Registration Trial will contain rules for assigning patients to treatments and other guidelines.Each of the five cooperative research groups in the NCI's National Clinical Trials Network (NCTN) will design and lead the treatment trials. Along with ECOG-ACRIN, the other network groups designing and leading subprotocols are the Alliance for Clinical Trials in Oncology, Children’s Oncology Group, NRG Oncology, and SWOG Cancer Research Network.
Like NCI-MATCH, the new trial will have multiple investigators leading each treatment arm. There will be opportunities for both junior and senior investigators to work alongside translational researchers.
ComboMATCH is projected to open in early 2023.